Please login to the form below

Not currently logged in
Email:
Password:

ANAVEX2-73

This page shows the latest ANAVEX2-73 news and features for those working in and with pharma, biotech and healthcare.

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

This is now the second independent placebo-controlled clinical ANAVEX2-73 phase 2 study to confirm the predictive biomarker of response established with SIGMAR1 mRNA expression. ... This data further strengthens the foundation of ANAVEX2-73 as a

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....